目的研究分析应用表柔比星联合紫杉醇的新辅助化疗方法治疗三阴性乳腺癌的效果。方法经筛选将昆明医科大学第三附属医院40例三阴性乳腺癌患者做为研究对象,采用应用表柔比星联合紫杉醇的新辅助化疗法进行治疗,分别测定其治疗前后叉头框...目的研究分析应用表柔比星联合紫杉醇的新辅助化疗方法治疗三阴性乳腺癌的效果。方法经筛选将昆明医科大学第三附属医院40例三阴性乳腺癌患者做为研究对象,采用应用表柔比星联合紫杉醇的新辅助化疗法进行治疗,分别测定其治疗前后叉头框蛋白A1(fork box protein A1,FOXA1)、乳腺癌易感基因(breast cancer susceptibility gene 1,BRCA1)蛋白表达水平、肿瘤直径大小。结果治疗后,患者的FOXA1、BRCA1蛋白表达水平降低,与治疗前相比差异具有统计学意义(P<0.05);治疗后,患者肿瘤直径减小,与治疗前相比差异具有统计学意义(P<0.01)。结论采用应用表柔比星联合紫杉醇的新辅助化疗,对三阴性乳腺癌患者进行治疗,治疗后疗效显著,FOXA1、BRCA1水平改善,肿瘤直径减小。展开更多
Background Superficial bladder cancer accounts for 60%-70% of all bladder cancer cases in China, when treatment consists of only transurethral resection of the bladder tumor （TUR-BT）, recurrence and progresses in th...Background Superficial bladder cancer accounts for 60%-70% of all bladder cancer cases in China, when treatment consists of only transurethral resection of the bladder tumor （TUR-BT）, recurrence and progresses in the bladder are observed in some patients. There are numerous reports of trials of intravesical instillation of anticancer agents with the objective of lowering this recurrence rate. The aim of this study was to compare the prophylactic efficacy and safety of epirubicin （EPI）, pirarubicin （THP） and hydroxycamptothecin （HCPT） in superficial bladder cancer.Methods This study enrolled a total of 189 patients who had been diagnosed with superficial bladder cancer during the period from 2004 through 2007 at Beijing Friendship Hospital. All patients were randomly allocated to one of three treatment groups. Patients in group A received 29 doses of EPI 30 mg/30 ml, patients in group B received 29 doses of THP 30 mg/30 ml, and patients in group C received 29 doses of HCPT 30 mg/30 ml, over a period of 24 months.Results The recurrence-free rate in the 2 anthracycline treatment groups （A and B） were significantly better than that of the HCPT treatment group. In the safety evaluation, the incidences of pollakiuria, pain on urination, dysuria, hematuria,and contracted bladder were not significantly different between groups A and B, but some were significantly higher in groups A and B than that in group C.Conclusion The efficacy of EPI and THP was significantly better than HCPT in the prevention of bladder cancer recurrence.展开更多
文摘目的研究分析应用表柔比星联合紫杉醇的新辅助化疗方法治疗三阴性乳腺癌的效果。方法经筛选将昆明医科大学第三附属医院40例三阴性乳腺癌患者做为研究对象,采用应用表柔比星联合紫杉醇的新辅助化疗法进行治疗,分别测定其治疗前后叉头框蛋白A1(fork box protein A1,FOXA1)、乳腺癌易感基因(breast cancer susceptibility gene 1,BRCA1)蛋白表达水平、肿瘤直径大小。结果治疗后,患者的FOXA1、BRCA1蛋白表达水平降低,与治疗前相比差异具有统计学意义(P<0.05);治疗后,患者肿瘤直径减小,与治疗前相比差异具有统计学意义(P<0.01)。结论采用应用表柔比星联合紫杉醇的新辅助化疗,对三阴性乳腺癌患者进行治疗,治疗后疗效显著,FOXA1、BRCA1水平改善,肿瘤直径减小。
文摘Background Superficial bladder cancer accounts for 60%-70% of all bladder cancer cases in China, when treatment consists of only transurethral resection of the bladder tumor （TUR-BT）, recurrence and progresses in the bladder are observed in some patients. There are numerous reports of trials of intravesical instillation of anticancer agents with the objective of lowering this recurrence rate. The aim of this study was to compare the prophylactic efficacy and safety of epirubicin （EPI）, pirarubicin （THP） and hydroxycamptothecin （HCPT） in superficial bladder cancer.Methods This study enrolled a total of 189 patients who had been diagnosed with superficial bladder cancer during the period from 2004 through 2007 at Beijing Friendship Hospital. All patients were randomly allocated to one of three treatment groups. Patients in group A received 29 doses of EPI 30 mg/30 ml, patients in group B received 29 doses of THP 30 mg/30 ml, and patients in group C received 29 doses of HCPT 30 mg/30 ml, over a period of 24 months.Results The recurrence-free rate in the 2 anthracycline treatment groups （A and B） were significantly better than that of the HCPT treatment group. In the safety evaluation, the incidences of pollakiuria, pain on urination, dysuria, hematuria,and contracted bladder were not significantly different between groups A and B, but some were significantly higher in groups A and B than that in group C.Conclusion The efficacy of EPI and THP was significantly better than HCPT in the prevention of bladder cancer recurrence.
